| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating pharmaceutical structure-guided drug design: a successful model
|
Keefe, Lisa J.
|
|
2019
|
24 |
2 |
p. 377-381
|
artikel
|
| 2 |
Accomplishments and challenges in stem cell imaging in vivo
|
Bose, Rajendran J.C.
|
|
2019
|
24 |
2 |
p. 492-504
|
artikel
|
| 3 |
Advances in particle shape engineering for improved drug delivery
|
Yang, Yiwei
|
|
2019
|
24 |
2 |
p. 575-583
|
artikel
|
| 4 |
Advancing nonclinical innovation and safety in pharmaceutical testing
|
Baker, Elizabeth J.
|
|
2019
|
24 |
2 |
p. 624-628
|
artikel
|
| 5 |
Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein–protein interaction inhibitors
|
Trisciuzzi, Daniela
|
|
2019
|
24 |
2 |
p. 551-559
|
artikel
|
| 6 |
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
|
Wilkinson, Samuel T.
|
|
2019
|
24 |
2 |
p. 606-615
|
artikel
|
| 7 |
Application of nanotechnology to improve the therapeutic benefits of statins
|
Korani, Shahla
|
|
2019
|
24 |
2 |
p. 567-574
|
artikel
|
| 8 |
A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade
|
Easa, Najma
|
|
2019
|
24 |
2 |
p. 440-451
|
artikel
|
| 9 |
Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors
|
Jing, Lanlan
|
|
2019
|
24 |
2 |
p. 629-635
|
artikel
|
| 10 |
Contents page 2
|
|
|
2019
|
24 |
2 |
p. ii
|
artikel
|
| 11 |
Contents page 1
|
|
|
2019
|
24 |
2 |
p. i
|
artikel
|
| 12 |
Essential oils: from prevention to treatment of skin cancer
|
Pavithra, P.S.
|
|
2019
|
24 |
2 |
p. 644-655
|
artikel
|
| 13 |
Evolution of commercially available compounds for HTS
|
Volochnyuk, Dmitriy M.
|
|
2019
|
24 |
2 |
p. 390-402
|
artikel
|
| 14 |
Growing synergy of nanodiamonds in neurodegenerative interventions
|
Saraf, Jackson
|
|
2019
|
24 |
2 |
p. 584-594
|
artikel
|
| 15 |
Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption
|
Hatton, Grace B.
|
|
2019
|
24 |
2 |
p. 417-427
|
artikel
|
| 16 |
Impact of dosing schedule in animal experiments on compound progression decisions
|
Chen, Chao
|
|
2019
|
24 |
2 |
p. 371-376
|
artikel
|
| 17 |
Interplay between hereditary and environmental factors to establish an in vitro disease model of keratoconus
|
Roy, Subhadeep
|
|
2019
|
24 |
2 |
p. 403-416
|
artikel
|
| 18 |
Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery
|
Kinch, Michael S.
|
|
2019
|
24 |
2 |
p. 382-389
|
artikel
|
| 19 |
Meeting the discovery challenge of drug-resistant infections: progress and focusing resources
|
Dougan, Gordon
|
|
2019
|
24 |
2 |
p. 452-461
|
artikel
|
| 20 |
Microtransplantation of human brain receptors into oocytes to tackle key questions in drug discovery
|
Zwart, Ruud
|
|
2019
|
24 |
2 |
p. 533-543
|
artikel
|
| 21 |
Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation
|
Nabil, Ghazal
|
|
2019
|
24 |
2 |
p. 462-491
|
artikel
|
| 22 |
Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer’s disease
|
Pradeepkiran, Jangampalli Adi
|
|
2019
|
24 |
2 |
p. 616-623
|
artikel
|
| 23 |
Recent advances in pharmaceutical dosage forms and devices using additive manufacturing technologies
|
Gioumouxouzis, Christos I.
|
|
2019
|
24 |
2 |
p. 636-643
|
artikel
|
| 24 |
Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets
|
Günther, Sven
|
|
2019
|
24 |
2 |
p. 428-439
|
artikel
|
| 25 |
Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases
|
Wang, Zi-Ying
|
|
2019
|
24 |
2 |
p. 595-605
|
artikel
|
| 26 |
Targeting VEGF–neuropilin interactions: a promising antitumor strategy
|
Peng, Kewen
|
|
2019
|
24 |
2 |
p. 656-664
|
artikel
|
| 27 |
The essentiality of drug targets: an analysis of current literature and genomic databases
|
Ji, Xiao
|
|
2019
|
24 |
2 |
p. 544-550
|
artikel
|
| 28 |
The future R&D landscape in non-alcoholic steatohepatitis (NASH)
|
Black, Darcey
|
|
2019
|
24 |
2 |
p. 560-566
|
artikel
|
| 29 |
The leukotriene signaling pathway: a druggable target in Alzheimer’s disease
|
Michael, Johanna
|
|
2019
|
24 |
2 |
p. 505-516
|
artikel
|
| 30 |
The power of combining phenotypic and target-focused drug discovery
|
Heilker, Ralf
|
|
2019
|
24 |
2 |
p. 526-532
|
artikel
|
| 31 |
Toward improving drug delivery research in Egypt: Cancer Nanotechnology Research Laboratory (CNRL) as a role model
|
Elzoghby, Ahmed O.
|
|
2019
|
24 |
2 |
p. 361-363
|
artikel
|
| 32 |
Towards the development of human immune-system-on-a-chip platforms
|
Polini, Alessandro
|
|
2019
|
24 |
2 |
p. 517-525
|
artikel
|
| 33 |
Trends in interorganizational transactions in personalized medicine development
|
Makino, Tomohiro
|
|
2019
|
24 |
2 |
p. 364-370
|
artikel
|
Tijdschrift beschrijving